BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Infographics: Dynamic digital data analysis
Trump administration impacts
Biopharma M&A scorecard
BioWorld 2024 review
BioWorld MedTech 2024 review
BioWorld Science 2024 review
Women's health
China's GLP-1 landscape
PFA re-energizes afib market
China CAR T
Alzheimer's disease
Israel
Rise of obesity
Radiopharmaceuticals
Biosimilars
Aging
IVDs on the rise
Coronavirus
Artificial intelligence
BioWorld. Link to homepage.
Sign In
Sign Out
My Account
Subscribe
BioWorld - Tuesday, February 18, 2025
See today's BioWorld
Home
» Little Impact to Ariad as Taltorvic Sinks Without a Ripple on CRL
To read the full story,
subscribe
or
sign in
.
Little Impact to Ariad as Taltorvic Sinks Without a Ripple on CRL
June 7, 2012
By
Catherine Shaffer
No Comments
As anticipated, the FDA issued a complete response letter for Taltorvic (ridaforolimus) from Merck & Co. Inc. and Ariad Pharmaceuticals Inc. as a maintenance therapy for metastatic sarcoma.
BioWorld
